2026-2034年糖尿病神經病變治療全球市場規模、佔有率、趨勢和成長分析報告

預計糖尿病神經病變治療市場規模將從 2025 年的 57 億美元成長到 2034 年的 112.7 億美元，並有望從 2026 年到 2034 年以 7.88% 的複合年成長率成長。

全球糖尿病及其併發症併發症的不斷上升，正在推動糖尿病神經病變治療市場的發展。糖尿病神經病變以神經損傷和慢性疼痛為特徵，影響相當一部分糖尿病患者。人們對早期診斷和管理糖尿病相關併發症重要性的認知不斷提高，也推動了對糖尿病神經病變治療的需求。

關鍵成長要素包括新型疼痛管理藥物的研發和血糖控制療法的改進。老年人口的增加和久坐的生活方式導致糖尿病發病率上升，進一步推動了市場成長。此外，聯合治療和緩釋製劑的進步也提高了治療效果。

鑑於疾病修正治療的進展，市場前景依然強勁。新興地區醫療保健投資的增加將改善患者獲得治療的機會。將數位健康監測工具應用於糖尿病管理，也可能間接促進神經病變治療的需求。持續創新，開發更安全、更有效的治療方案，將塑造市場的長期成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球糖尿病神經病變治療市場：依疾病類型分類

• 市場分析、洞察與預測
• 周邊神經病變
• 自主神經病變
• 近端神經病變
• 局部神經病變

第5章 全球糖尿病神經病變治療市場：依藥物類別分類

• 市場分析、洞察與預測
• 辣椒素
• 鴉片類藥物
• 非類固醇消炎劑（NSAIDs）
• 抗憂鬱症
• 其他

第6章 全球糖尿病神經病變治療市場：依通路分類

• 市場分析、洞察與預測
• 醫院和藥房
• 零售藥房
• 其他

第7章 全球糖尿病神經病變治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Abbott Laboratories
  • Eli Lilly And Company
  • Pfizer Inc
  • Janssen Pharmaceuticals Inc
  • Lupin Limited
  • Astellas Pharma Inc
  • Glenmark Pharmaceuticals Limited
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • Novartis AG
  • Sanofi

The Diabetic Neuropathy Treatment Market size is expected to reach USD 11.27 Billion in 2034 from USD 5.70 Billion (2025) growing at a CAGR of 7.88% during 2026-2034.

The Global Diabetic Neuropathy Treatment Market is expanding due to the increasing global prevalence of diabetes and its associated complications. Diabetic neuropathy, characterized by nerve damage and chronic pain, affects a significant portion of diabetic patients. Rising awareness about early diagnosis and management of diabetes-related complications is driving treatment demand.

Major growth drivers include the development of novel pain management drugs and improved glycemic control therapies. Growing geriatric populations and sedentary lifestyles are contributing to higher diabetes incidence rates, further supporting market growth. Additionally, advancements in combination therapies and extended-release formulations are enhancing treatment effectiveness.

Future prospects remain strong as research into disease-modifying therapies progresses. Increasing healthcare investments in emerging regions will improve treatment accessibility. Integration of digital health monitoring tools for diabetes management may also indirectly support neuropathy treatment demand. Continuous innovation in safer and more effective therapeutic options will shape long-term market growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Disorder Type

• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy

By Drug Class

• Capsaicin
• Opioid
• Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
• Antidepressants
• Other

By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Other

COMPANIES PROFILED

• Abbott Laboratories, Eli Lilly and Company, Pfizer Inc, Janssen Pharmaceuticals Inc, Lupin Limited, Astellas Pharma Inc, Glenmark Pharmaceuticals Limited, Boehringer Ingelheim Pharma GmbH Co KG, Novartis AG, Sanofi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET: BY DISORDER TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disorder Type
• 4.2. Peripheral Neuropathy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Autonomic Neuropathy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Proximal Neuropathy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Focal Neuropathy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Capsaicin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Opioid Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Antidepressants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospitals Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Disorder Type
  • 7.2.2 By Drug Class
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Disorder Type
  • 7.3.2 By Drug Class
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Disorder Type
  • 7.4.2 By Drug Class
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Disorder Type
  • 7.5.2 By Drug Class
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Disorder Type
  • 7.6.2 By Drug Class
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL DIABETIC NEUROPATHY TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Abbott Laboratories
  • 9.2.2 Eli Lilly And Company
  • 9.2.3 Pfizer Inc
  • 9.2.4 Janssen Pharmaceuticals Inc
  • 9.2.5 Lupin Limited
  • 9.2.6 Astellas Pharma Inc
  • 9.2.7 Glenmark Pharmaceuticals Limited
  • 9.2.8 Boehringer Ingelheim Pharma GmbH & Co. KG
  • 9.2.9 Novartis AG
  • 9.2.10 Sanofi